HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock Fundamental Analysis

NASDAQ:HRMY • US4131971040

28.19 USD
+1.32 (+4.91%)
At close: Feb 24, 2026
28.3 USD
+0.11 (+0.39%)
Pre-Market: 2/25/2026, 8:21:43 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall HRMY gets a fundamental rating of 7 out of 10. We evaluated HRMY against 192 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making HRMY a very profitable company, without any liquidiy or solvency issues. HRMY is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make HRMY suitable for value investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year HRMY was profitable.
  • In the past year HRMY had a positive cash flow from operations.
  • Of the past 5 years HRMY 4 years were profitable.
  • Of the past 5 years HRMY 4 years had a positive operating cash flow.
HRMY Yearly Net Income VS EBIT VS OCF VS FCFHRMY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

  • HRMY has a better Return On Assets (15.37%) than 95.31% of its industry peers.
  • With an excellent Return On Equity value of 22.23%, HRMY belongs to the best of the industry, outperforming 92.19% of the companies in the same industry.
  • HRMY has a Return On Invested Capital of 17.20%. This is amongst the best in the industry. HRMY outperforms 94.79% of its industry peers.
  • HRMY had an Average Return On Invested Capital over the past 3 years of 18.27%. This is significantly above the industry average of 12.96%.
Industry RankSector Rank
ROA 15.37%
ROE 22.23%
ROIC 17.2%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
HRMY Yearly ROA, ROE, ROICHRMY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • HRMY has a better Profit Margin (22.48%) than 91.67% of its industry peers.
  • In the last couple of years the Profit Margin of HRMY has grown nicely.
  • The Operating Margin of HRMY (27.32%) is better than 92.19% of its industry peers.
  • In the last couple of years the Operating Margin of HRMY has declined.
  • With an excellent Gross Margin value of 77.70%, HRMY belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
  • HRMY's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.32%
PM (TTM) 22.48%
GM 77.7%
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
HRMY Yearly Profit, Operating, Gross MarginsHRMY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), HRMY is creating value.
  • There is no outstanding debt for HRMY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HRMY Yearly Shares OutstandingHRMY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
HRMY Yearly Total Debt VS Total AssetsHRMY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 4.68 indicates that HRMY is not in any danger for bankruptcy at the moment.
  • HRMY has a better Altman-Z score (4.68) than 74.48% of its industry peers.
  • HRMY has a debt to FCF ratio of 0.57. This is a very positive value and a sign of high solvency as it would only need 0.57 years to pay back of all of its debts.
  • HRMY has a better Debt to FCF ratio (0.57) than 96.88% of its industry peers.
  • HRMY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.18, HRMY perfoms like the industry average, outperforming 45.31% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.57
Altman-Z 4.68
ROIC/WACC1.83
WACC9.38%
HRMY Yearly LT Debt VS Equity VS FCFHRMY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • HRMY has a Current Ratio of 3.75. This indicates that HRMY is financially healthy and has no problem in meeting its short term obligations.
  • HRMY's Current ratio of 3.75 is in line compared to the rest of the industry. HRMY outperforms 57.29% of its industry peers.
  • A Quick Ratio of 3.72 indicates that HRMY has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.72, HRMY perfoms like the industry average, outperforming 58.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.75
Quick Ratio 3.72
HRMY Yearly Current Assets VS Current LiabilitesHRMY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 7.97% over the past year.
  • Measured over the past years, HRMY shows a decrease in Earnings Per Share. The EPS has been decreasing by -4.69% on average per year.
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.12%

3.2 Future

  • HRMY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.60% yearly.
  • HRMY is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.49% yearly.
EPS Next Y59.48%
EPS Next 2Y40.12%
EPS Next 3Y54.88%
EPS Next 5Y35.6%
Revenue Next Year16.97%
Revenue Next 2Y14.81%
Revenue Next 3Y14.6%
Revenue Next 5Y9.49%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
HRMY Yearly Revenue VS EstimatesHRMY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B
HRMY Yearly EPS VS EstimatesHRMY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

10

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 10.40 indicates a reasonable valuation of HRMY.
  • Based on the Price/Earnings ratio, HRMY is valued cheaper than 91.15% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of HRMY to the average of the S&P500 Index (26.98), we can say HRMY is valued rather cheaply.
  • HRMY is valuated cheaply with a Price/Forward Earnings ratio of 6.52.
  • 93.75% of the companies in the same industry are more expensive than HRMY, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of HRMY to the average of the S&P500 Index (28.01), we can say HRMY is valued rather cheaply.
Industry RankSector Rank
PE 10.4
Fwd PE 6.52
HRMY Price Earnings VS Forward Price EarningsHRMY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, HRMY is valued cheaper than 97.92% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, HRMY is valued cheaper than 96.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.47
EV/EBITDA 4.38
HRMY Per share dataHRMY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HRMY has an outstanding profitability rating, which may justify a higher PE ratio.
  • HRMY's earnings are expected to grow with 54.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.17
PEG (5Y)N/A
EPS Next 2Y40.12%
EPS Next 3Y54.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • HRMY does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HARMONY BIOSCIENCES HOLDINGS

NASDAQ:HRMY (2/24/2026, 8:00:02 PM)

Premarket: 28.3 +0.11 (+0.39%)

28.19

+1.32 (+4.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners85.16%
Inst Owner Change4.25%
Ins Owners1.63%
Ins Owner Change-61.66%
Market Cap1.62B
Revenue(TTM)N/A
Net Income(TTM)185.68M
Analysts78.82
Price Target46.55 (65.13%)
Short Float %11.62%
Short Ratio8.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.77%
Min EPS beat(2)-11.17%
Max EPS beat(2)1.62%
EPS beat(4)3
Avg EPS beat(4)8.56%
Min EPS beat(4)-11.17%
Max EPS beat(4)31%
EPS beat(8)6
Avg EPS beat(8)57.65%
EPS beat(12)9
Avg EPS beat(12)44.35%
EPS beat(16)12
Avg EPS beat(16)96.55%
Revenue beat(2)1
Avg Revenue beat(2)0.75%
Min Revenue beat(2)-3.46%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-3.46%
Max Revenue beat(4)4.96%
Revenue beat(8)1
Avg Revenue beat(8)-1%
Revenue beat(12)3
Avg Revenue beat(12)-0.86%
Revenue beat(16)5
Avg Revenue beat(16)-0.67%
PT rev (1m)0.79%
PT rev (3m)2%
EPS NQ rev (1m)-1.49%
EPS NQ rev (3m)1.86%
EPS NY rev (1m)0.65%
EPS NY rev (3m)0.83%
Revenue NQ rev (1m)0.32%
Revenue NQ rev (3m)0.98%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)2.29%
Valuation
Industry RankSector Rank
PE 10.4
Fwd PE 6.52
P/S 1.97
P/FCF 5.47
P/OCF 5.46
P/B 1.94
P/tB 2.2
EV/EBITDA 4.38
EPS(TTM)2.71
EY9.61%
EPS(NY)4.32
Fwd EY15.33%
FCF(TTM)5.15
FCFY18.28%
OCF(TTM)5.17
OCFY18.33%
SpS14.34
BVpS14.5
TBVpS12.84
PEG (NY)0.17
PEG (5Y)N/A
Graham Number29.73
Profitability
Industry RankSector Rank
ROA 15.37%
ROE 22.23%
ROCE 22.91%
ROIC 17.2%
ROICexc 54.26%
ROICexgc 78.12%
OM 27.32%
PM (TTM) 22.48%
GM 77.7%
FCFM 35.95%
ROA(3y)19.12%
ROA(5y)10.08%
ROE(3y)31.57%
ROE(5y)9.53%
ROIC(3y)18.27%
ROIC(5y)15.29%
ROICexc(3y)40.78%
ROICexc(5y)37.48%
ROICexgc(3y)77.32%
ROICexgc(5y)N/A
ROCE(3y)24.34%
ROCE(5y)20.37%
ROICexgc growth 3Y-76.77%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.89%
ROICexc growth 5YN/A
OM growth 3Y-2.32%
OM growth 5YN/A
PM growth 3Y21.57%
PM growth 5YN/A
GM growth 3Y-1.56%
GM growth 5Y1.26%
F-Score6
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 0.57
Debt/EBITDA 0.6
Cap/Depr 3%
Cap/Sales 0.09%
Interest Coverage 14.73
Cash Conversion 119.28%
Profit Quality 159.9%
Current Ratio 3.75
Quick Ratio 3.72
Altman-Z 4.68
F-Score6
WACC9.38%
ROIC/WACC1.83
Cap/Depr(3y)59.29%
Cap/Depr(5y)142.27%
Cap/Sales(3y)3.13%
Cap/Sales(5y)8.45%
Profit Quality(3y)125.93%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.97%
EPS 3Y-4.69%
EPS 5YN/A
EPS Q2Q%-55.29%
EPS Next Y59.48%
EPS Next 2Y40.12%
EPS Next 3Y54.88%
EPS Next 5Y35.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%21.12%
Revenue Next Year16.97%
Revenue Next 2Y14.81%
Revenue Next 3Y14.6%
Revenue Next 5Y9.49%
EBIT growth 1Y17.58%
EBIT growth 3Y29.68%
EBIT growth 5YN/A
EBIT Next Year37.6%
EBIT Next 3Y23.97%
EBIT Next 5Y24.08%
FCF growth 1Y75.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.68%
OCF growth 3Y30.64%
OCF growth 5YN/A

HARMONY BIOSCIENCES HOLDINGS / HRMY FAQ

Can you provide the ChartMill fundamental rating for HARMONY BIOSCIENCES HOLDINGS?

ChartMill assigns a fundamental rating of 8 / 10 to HRMY.


What is the valuation status of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

ChartMill assigns a valuation rating of 9 / 10 to HARMONY BIOSCIENCES HOLDINGS (HRMY). This can be considered as Undervalued.


Can you provide the profitability details for HARMONY BIOSCIENCES HOLDINGS?

HARMONY BIOSCIENCES HOLDINGS (HRMY) has a profitability rating of 8 / 10.


What are the PE and PB ratios of HARMONY BIOSCIENCES HOLDINGS (HRMY) stock?

The Price/Earnings (PE) ratio for HARMONY BIOSCIENCES HOLDINGS (HRMY) is 10.4 and the Price/Book (PB) ratio is 1.94.


What is the earnings growth outlook for HARMONY BIOSCIENCES HOLDINGS?

The Earnings per Share (EPS) of HARMONY BIOSCIENCES HOLDINGS (HRMY) is expected to grow by 59.48% in the next year.